ArticleScientific reports2017
Safety of Nonporous Silica Nanoparticles in Human Corneal Endothelial Cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Autophagy modulation in animal models of corneal diseases: a systematic review.Molecular and cellular biochemistry · 2020Pooled it
- Targeted AAV6 gene therapy restores corneal endothelial function in three hereditary corneal dystrophies.Cell reports. Medicine · 2026Article
- Hydrophobic Silicon Quantum Dots for Potential Imaging of Tear Film Lipid Layer.Nanomaterials (Basel, Switzerland) · 2025Article
- Article
- The impact of cell density variations on nanoparticle uptake across bioprinted A549 gradients.Frontiers in bioengineering and biotechnology · 2025Article
- Nanoparticle-Based Drug Delivery for Vascular Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Submicron immunoglobulin particles exhibit FcγRII-dependent toxicity linked to autophagy in TNFα-stimulated endothelial cells.Cellular and molecular life sciences : CMLS · 2024Article
- Review
- Ocular Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability.Pharmaceutics · 2022Article
- Retinal cytotoxicity of silica and titanium dioxide nanoparticles.Toxicology research · 2022Article
- Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.International journal of molecular sciences · 2021Review
- Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells.Scientific reports · 2021Article
- Safety and Toxicity Issues of Therapeutically Used Nanoparticles from the Oral Route.BioMed research international · 2021Review
- Silica Nanoparticles in Transmucosal Drug Delivery.Pharmaceutics · 2020Review
- Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment.Cellular and molecular life sciences : CMLS · 2019Review
- Effects of a novel peptide Ac-SDKP in radiation-induced coronary endothelial damage and resting myocardial blood flow.Cardio-oncology (London, England) · 2018Article
- Co-exposure subacute toxicity of silica nanoparticles and lead acetate on cardiovascular system.International journal of nanomedicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonporous silica nanoparticles (SiNPs) are promising drug carrier platforms for intraocular drug delivery. In this study, we investigated the safety of three different sizes of SiNPs (50, 100, and 150 nm) in a human corneal endothelial cell (HCEC) line, B4G12. The HCECs were exposed to different concentrations (0, 25, 50, and 100 µg/ml) of three sizes of SiNPs for up to 48 h. Cellular viability, autophagy, lactate dehydrogenase (LDH) assay, and mammalian target of rapamycin (mTOR) pathway activation were evaluated. Intracellular distribution of the SiNPs was evaluated with transmission electron microscopy (TEM). TEM revealed that the SiNPs were up-taken by the HCECs inside cytoplasmic vacuoles. No mitochondrial structural damage was observed. Both cellular viability and LDH level remained unchanged with up to 100 µg/mL of SiNP treatment. Autophagy showed a significant dose-dependent activation with 50, 100, and 150 nm SiNPs. However, the mTOR activation remained unchanged. Human corneal tissue culture with 100 µg/ml concentrations of SiNPs for 72 h revealed no significant endothelial toxicity. In vivo corneal safety of the SiNPs (0.05 ml intracameral injection, 200 mg/ml concentration) was also verified in rabbit models. These findings suggested that 50, 100, and 150 nm SiNPs did not induce acute significant cytotoxicity in corneal endothelial cells at concentrations up to 100 µg/mL. However, long-term toxicity of SiNPs remains unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.